Contribution of endothelin to coronary vasomotor tone is abolished after myocardial infarction

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 288, Issue 2 57-2, 2005, Pages

  Merkus, Daphne ^a   Houweling, Birgit ^a   Van Den Meiracker, Anton H ^a   Boomsma, Frans ^a   Duncker, Dirk J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Coronary blood flow; Coronary microcirculation; Left ventricular dysfunction; Myocardial oxygen balance

Indexed keywords

ENDOTHELIN; TEZOSENTAN;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CONSTRICTION; EXERCISE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE PERFUSION; HEART VENTRICLE REMODELING; MICROCIRCULATION; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SWINE;

ANIMALS; ARTERIOLES; CORONARY CIRCULATION; ENDOTHELIN-1; FEMALE; MALE; MYOCARDIAL INFARCTION; OXYGEN; PYRIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SUS SCROFA; TETRAZOLES; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 12344280850     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00429.2004     Document Type: Article

References (31)

1. Clozel M, Ramuz H, Clozel JP, Breu V, Hess P, Loffler BM, Coassolo P, and Roux S. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 290: 840-846, 1999.
2. Colucci WS and Braunwald E. Pathophysiology of heart failure. In: Mean Disease - A Textbook of Cardiovascular Medicine (6th ed.), edited by Braunwald E, Zipes DP, and Libby P. Philadelphia, PA: Saunders, 2001, p: 503-534.
3. Duncker DJ, Stubenitsky R, and Verdouw PD. Autonomic control of vasomotion in the porcine coronary circulation during treadmill exercise: evidence for feed-forward β-adrenergic control. Circ Res 82: 1312-1322, 1998.
4. Duncker DJ, Stubenitsky R, and Verdouw PD. Role of adenosine in the regulation of coronary blood flow in swine at rest and during treadmill exercise. Am J Physiol Heart Circ Physiol 275: H1663-H1672, 1998.
5. Feigl EO. Coronary physiology. Physiol Rev 63: 1-205, 1983.
6. Gottlieb SS. The neurohormonal paradigm: have we gone too far? J Am Coll Cardiol 41: 1458-1459, 2003.
7. Haitsma DB, Bac D, Raja N, Boomsma F, Verdouw PD, and Duncker DJ. Minimal impairment of myocardial blood flow responses to exercise in the remodeled left ventricle early after myocardial infarction, despite significant hemodynamic and neurohumoral alterations. Cardiovasc Res 52: 417-428, 2001.
8. Haitsma DB, Merkus D, Vermeiden J, Verdouw PD, and Duncker DJ. Nitric oxide production is maintained in exercising swine with chronic left ventricular dysfunction. Am J Physiol Heart Circ Physiol 282: H2198-H2209, 2002.
9. Kalkman EA, Bilgin YM, van Haren P, van Suylen RJ, Saxena PR, and Schoemaker RG. Determinants of coronary reserve in rats subjected to coronary artery ligation or aortic banding. Cardiovasc Res 32: 1088-1095, 1996.
10. Karam R, Healy BP, and Wicker P. Coronary reserve is depressed in postmyocardial infarction reactive cardiac hypertrophy. Circulation 81: 238-246, 1990.
11. Kjekshus H, Smiseth OA, Klinge R, Oie E, Hystad ME, and Attramadal H. Regulation of ET: pulmonary release of ET contributes to increased plasma ET levels and vasoconstriction in CHF. Am J Physiol Heart Circ Physiol 278: H1299-H1310, 2000.
12. B receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am J Physiol Heart Circ Physiol 276: H1197-H1206, 1999.
13. Kuo L, Davis MJ, and Chilian WM. Myogenic activity in isolated subepicardial and subendocardial coronary arterioles. Am J Physiol Heart Circ Physiol 255: H1558-H1562, 1988.
14. A receptor antagonist. Circulation 101: 142-147, 2000.
15. A selective antagonist. Bioorg Med Chem Lett 8: 1771-1776, 1998.
16. Merkus D, Chilian WM, and Stepp DW. Functional characteristics of the coronary microcirculation. Herz 24: 496-508, 1999.
17. Merkus D, Duncker DJ, and Chilian WM. Metabolic regulation of coronary vascular tone: role of endothelin-1. Am J Physiol Heart Circ Physiol 283: H1915-H1921, 2002.
18. Merkus D, Houweling B, Mirza A, Boomsma F, van den Meiracker AH, and Duncker DJ. Contribution of endothelin and its receptors to the regulation of vascular tone during exercise is different in the systemic, coronary and pulmonary circulation. Cardiovasc Res 59: 745-754, 2003.
19. Merkus D, Stepp DW, Jones DW, Nishikawa Y, and Chilian WM. Adenosine preconditions against endothelin-induced constriction of coronary arterioles. Am J Physiol Heart Circ Physiol 279: H2593-H2597, 2000.
20. O'Connor CM, Gattis WA, Adams KF Jr, Hasselblad V, Chandler B, Frey A, Kobrin I, Rainisio M, Shah MR, Teerlink J, and Gheorghiade M. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol 41: 1452-1457, 2003.
21. Ohnishi M, Wada A, Tsutamoto T, Fukai D, Sawaki M, Maeda Y, and Kinoshita M. Chronic effects of a novel, orally active endothelin receptor antagonist, T-0201, in dogs with congestive heart failure. J Cardiovasc Pharmacol 31: S236-S238, 1998.
22. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, Yamaguchi I, Goto K, and Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 93: 1214-1222, 1996.
23. Spieker LE, Noll G, Ruschitzka FT, and Luscher TF. Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched? Heart Fail Rev 6: 301-315, 2001.
24. Spieker LE, Noll G, Ruschitzka FT, and Luscher TF. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol 37: 1493-1505, 2001.
25. 2 delivery and utilization in swine during treadmill exercise. Cardiovasc Res 39: 459-474, 1998.
26. B-receptor blockade on coronary responses to treadmill exercise in dogs. J Appl Physiol 89: 2041-2048, 2000.
27. Tune JD, Richmond KN, Gorman MW, and Feigl EO. Control of coronary blood flow during exercise. Exp Biol Med (Maywood) 227: 238-250, 2002.
28. Van Kate JP, Duncker DJ, Haitsma DB, Schuijt MP, Niebuur R, Stubenitsky R, Boomsma F, Schalekamp MA, Verdouw PD, and Danser AH. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation 102: 1556-1563, 2000.
29. Wackenfors A, Emilson M, Ingemansson R, Hortobagyi T, Szok D, Tajti J, Vecsei L, Edvinsson L, and Malmsjo M. Ischemic heart disease induces upregulation of endothelin receptor mRNA in human coronary arteries. Eur J Pharmacol 484: 103-109, 2004.
30. 31P-MRS study. Circulation 94: 1089-1100, 1996.
31. Zolk O, Quattek J, Sitzler G, Schrader T, Nickenig G, Schnabel P, Shimada K, Takahashi M, and Bohm M. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 99: 2118-2123, 1999.